CAPR Rasio cepet Capricor Therapeutics Inc.

Serving as the primary valuation tool, this Capricor Therapeutics (CAPR) price chart demonstrates the asset's dynamics, with a value of 7.08. Business stability is ensured by the absence of external conflicts and the localization of all development within the US. Capricor Therapeutics (CAPR) has created a unique cell therapy production cycle based on the CAP-1002 platform, while management focuses on identifying global partners to bring muscular dystrophy treatments to market.

This indicator determines the issuer's ability to instantaneously settle short-term debts without liquidating inventory. The metric compares the total of cash and accounts receivable against current liabilities, excluding illiquid assets. By analyzing the quick ratio, an investor assesses the risk of cash flow gaps. The stability of this coefficient guarantees that Capricor Therapeutics (CAPR) can fund high-paid specialists and support cutting-edge developments in the field of cell therapy.